fiercepharma.com
Most recent 1 articles
Mylan's Lantus copy derailed in U.S. again by manufacturing ills
When Biocon’s insulin operations in Malaysia won EU approval two weeks ago, it sounded like the company had turned a quality corner. But that turn is not near sharp enough for the FDA, which has issued a second complete response letter (CRL) for the Lantus competitor Biocon developed with Mylan.…